Abstract. In a cross-sectional survey carried out in west Africa (The Gambia), where Plasmodium falciparum malaria is endemic with seasonal transmission, 178 individuals 1-75 years of age were assessed for their antibody response to the malaria vaccine candidate, merozoite surface protein 2 (MSP2). Total IgG to recombinant antigens representing full-length, repetitive, and group-specific domains of both allelic families of MSP2 was determined by ELISA. The IgG-subclass profile of IgG-positive sera was assessed. Antibody prevalence was age-dependent, reaching a peak during adolescence. In MSP2-seropositive individuals, there was a predominance of cytophilic antibodies (IgG1 and IgG3); IgG1 antibodies were prevalent in children less than 10 years of age, whereas in adolescents and adults MSP2-specific antibodies were predominantly IgG3. In parallel, we conducted a longitudinal study of children (3-8 years of age) from the same community; sera collected before the malaria transmission season were tested for the presence of anti-MSP2 antibodies. The subsequent susceptibility of these children to clinical malaria was monitored and the association between anti-MSP2 antibodies of different IgG subclasses and resistance to clinical malaria was tested. The presence of IgG3 antibodies to MSP2 serogroup A was negatively associated with the risk of clinical malaria whereas IgG1 antibodies to MSP2 serogroup B were associated with an increased risk of clinical infection. Our data suggest that age/exposure-related acquisition of IgG3 antibodies to MSP2 may contribute to the development of clinically protective immunity to malaria.
In areas with stable endemic Plasmodium falciparum malaria transmission, parasitemia is most common in young children, with the incidence of parasitemia decreasing steadily with age. The precise timing of events depends on local patterns of malaria transmission and levels of endemicity. In The Gambia, where transmission is seasonal but stable from year to year, parasite rates do not begin to decrease until 10-12 years of age, whereas the incidence of clinical disease peaks at six years of age; in the same population, peak mortality from malaria occurs in children four years of age. 1 Various factors are thought to contribute to the slow development of immunity to malaria. Many malaria antigens are antigenically diverse and it has been proposed that protective immunity is dependent upon cumulative exposure to the many parasite variants circulating in the local population. 2 Critical malaria antigens may be poorly immunogenic and immunologic nonresponsiveness may be the result of parasite antigens evolving, presenting limited T cell epitopes to the immune system and thus failing to give T cell help for antibody production. 3 It has also been proposed that host age itself is a determinant of naturally acquired immunity such that protection is governed by a relatively brief heavy exposure and some intrinsic immune factor(s) associated with the age of the host. 4 However, this hypothesis cannot easily be demonstrated in populations from malaria endemic areas where age and exposure are directly related.
It is becoming apparent that the functional specificity of antibodies to malaria antigens may play an important role in the protective immune response. [5] [6] [7] [8] In vivo protective immunity to malaria correlates with in vitro inhibition of parasite growth by immune IgG in the presence of blood monocytes. 5, 7 If ancillary cells are required for antibody-mediated immunity, the isotype or subclass of the relevant antibodies is an important variable to consider; an individual may not be protected until there are sufficient levels of antibodies of the correct specificity and appropriate subclass. 6, 8 Indeed, it has been shown that IgG1 and IgG3 (cytophilic and complement fixing) antibodies specific for mature schizonts predominate in individuals protected from clinical malaria. 8 Although the antigenic specificity of these antibodies has not been established it is likely that the antibodies recognize accessible antigen on the surface of the merozoite. 5 There are several antigens associated with the merozoite surface of P. falciparum; one of these is the merozoite surface protein 2 (MSP2), a polymorphic, integral membrane protein. 9 Alignment of MSP2 allelic sequences shows that the N-and C-termini of the protein are highly conserved among different P. falciparum isolates, whereas the large central region is variable. 10, 11 This central region contains two tandemly repeated amino acid sequences flanked by group-specific sequences that define the two prototypic allelic families: serogroup A (3D7-type) and serogroup B (FC27-type). The sequence, number, and length of the repeat sequences differs between and within the allelic families. 10 We have previously described the relative antigenicity of different regions of MSP2 in a seroepidemiologic study of malaria-immune Gambians. 12 In this adult population, the antibody prevalence reached 86%; the conserved regions of the molecule were poorly immunogenic and the majority of individuals recognized the group-specific or repetitive domains. Furthermore, the predominant subclass of MSP2-specific antibody was IgG3, a finding that has recently been confirmed in Solomon Islanders. 13 Merozoite surface protein 2-specific polyclonal and monoclonal antibodies, defining variable, linear epitopes, have been shown to inhibit in vitro parasite invasion and growth. 14, 15 Mice immunized with peptides from conserved regions of MSP2 were protected from challenge with asexual parasites of the murine malaria P. chabaudi 16 but the protective capacity of these peptides has not been confirmed in other models of infection. 17 However, a negative association between the presence of antibodies to MSP2 and risk of malarial fever was observed in a seroepidemiologic study in Papua New Guinea, suggesting a possible protective role for anti-MSP2 antibodies in natural infection. 18 To examine the role of anti-MSP2 antibodies in clinical immunity to malaria, we have tested serum samples from a Gambian community, in whom individual infection histories have been characterized over two successive transmission seasons, 19 for the presence and IgG subclass of antibodies to MSP2. Previous analyses of these serum samples have revealed a protective role for antibodies to the C-terminal region of merozoite surface protein 1 20 and the glutamate-rich protein, 21 but not for other antigens such as the circumsporozoite protein. 19 These sera have not previously been characterized for antibodies to MSP2. The study examined the response to MSP2 in an age cross-section of the population to determine the dynamics of acquisition and the subclass distribution of anti-MSP2 antibodies. We found that the prevalence of anti-MSP2 IgG is age-dependent; there is an age-dependent increase in both the prevalence and concentration of specific IgG3. One interpretation of this finding is that the antibody response becomes increasingly effective with age, following a switch to secretion of antigen-specific IgG3. To examine this hypothesis we looked for an association between the distribution of various subclasses of MSP2-specific IgG and resistance to the clinical symptoms of malaria infection in a longitudinal study of children who were actively acquiring immunity to malaria. We find that the presence of MSP2 serogroup A-specific IgG3 is associated with a significantly reduced risk of clinical malaria.
SUBJECTS, MATERIALS, AND METHODS

Subjects.
All subjects were residents of rural villages around the town of Farafenni, on the north bank of the Gambia river; informed consent was obtained from each adult and from the parent or guardian of children less than 16 years of age. In this area, the majority of clinical malaria cases occur in the three-month period from September to November each year. 1 Ethical approval for this study was granted by the Medical Research Council/Gambia Government Ethical Review Committee.
Cross-sectional survey. One hundred seventy-eight serum samples were obtained from a cross-sectional survey of the population (1-75 years of age). These sera were collected in October 1988 during the malaria transmission season.
Longitudinal survey. At the beginning of the malaria transmission season (May 1988), plasma samples were obtained from 355 children 3-8 years of age. During the following six-month period, each child was visited once a week by a field worker to assess their clinical status. Blood films were made and examined for malaria parasites from any child reporting a fever or with an axillary temperature Ն 37.5ЊC. The children were re-examined in November at the end of the malaria transmission season, and a fingerprick sample was obtained and examined for malaria parasites. With this information, it was possible to categorize the malaria experience of each child during the previous six months. 19 For the purposes of this study, only those children classified as having had a clinical episode of malaria (fever plus parasitemia Ն 5,000 parasites/l blood) or an asymptomatic infection (parasitemia on cross-sectional survey, or an increase in spleen size during the transmission season, in the absence of clinical symptoms at any time in the previous six months) were included in the analysis. Those in whom no evidence of infection was detected during follow-up or at the crosssectional surveys were not included as it was not possible to say whether they were truly resistant to infection, whether they had experienced an undetected asymptomatic infection, or whether they had simply not been bitten by an infectious mosquito.
Control sera. Control sera (n ϭ 50 for cross-sectional survey, n ϭ 15-20 for IgG subclass analysis of cross-sectional samples, n ϭ 40 for longitudinal survey) were obtained from European donors with no previous exposure to malaria.
Antigens. Merozoite surface protein 2. Six polypeptides derived from the merozoite surface protein MSP2 were kindly provided by Dr. J. McBride (University of Edinburgh). These were recombinant proteins fused to glutathione Stransferase (GST), expressed in Escherichia coli transfected with pGEX, as previously described. 12 We have confirmed that the recombinant proteins express essentially the same B cell epitopes as the native protein (Taylor R, Ph.D thesis, University of Edinburgh, 1995). The A1 and B1 antigens represent the full-length proteins of MSP2 serogroup A (3D7-like) and serogroup B (FC27-like), respectively. The A2 antigen represents the short amino-terminal group-specific region of MSP2 serogroup A plus the highly polymorphic, repetitive region of glycine, serine, and alanine-rich repeats from the isolate T9/96. The A3 antigen represents the threonine repeats and the carboxy-terminal group-specific region of serogroup A isolate RO33. The B2 and B3 antigens represent the equivalent regions of MSP2 serogroup B, derived from isolates K1 and T9/105, respectively.
Control. A control GST protein, purified from E. coli transfected with vectors lacking an insert, was used as a control to determine the nonspecific (background) binding of human IgG.
Enzyme-linked immunosorbent assay. The ELISAs to measure MSP2-specific IgG and IgG subclasses were performed as previously described. 12 Briefly, microtiter plates (Immulon-4; Dynatech, Billingshurst, United Kingdom) were coated overnight with 100 l/well of antigen in 0.1 M carbonate buffer (Na 2 CO 3 /NaHCO 3 ), and blocked for 5 hr at room temperature with 200 l/well of blocking buffer (1% [w/v] milk powder in phosphate-buffered saline [PBS]/ 0.05% Tween 20). Plates were washed three times with PBS/ 0.05% Tween 20 and 100 l/well of serum (diluted 1:1,000) was added to duplicate wells and incubated overnight at 4ЊC. Plates were washed and incubated with an optimal dilution of horseradish peroxidase-conjugated rabbit anti-human IgG antibody (Dako, Ltd., High Wycombe, United Kingdom) for 3 hr at room temperature.
For the detection of specific IgG subclasses, plates were incubated with murine monoclonal antibodies to each human IgG subclass (IgG1-NL16; Boehringer, Mannheim, Germany, IgG2-GOM1; Boehringer, IgG3-HP6050; Serotec, Oxford, United Kingdom, IgG4-RJ4; Boehringer), followed by an incubation with horseradish peroxidase-conjugated rabbit anti-mouse immunoglobulin antibody; each incubation was for 3 hr at room temperature. The subclass specificity of these reagents has been reported previously 12 and was reconfirmed prior to this study. The working dilutions of the subclass-specific reagents were determined by titration; all the reagents gave parallel titration curves and the concentration of each reagent was selected such that, for each subclass, an optical density (OD) of 1.0 represented an antibody concentration of 0.05 mg/ml, with the exception of IgG2 where an OD of 1.0 represented a concentration of 0.3 mg/ml (Taylor R, 1995, Ph.D thesis, University of Edinburgh).
All plates were developed at 4ЊC with H 2 O 2 as substrate and o-phenylenediamine as chromagen and the reaction was stopped after 10 min with 20 l/well of 2 M H 2 SO 4 . The OD was measured at a wavelength of 492 nm. Optimal concentrations of antigen and antibody were determined by checkerboard titrations.
Data analysis. The reactivity of sera with MSP2 polypeptides was calculated by subtracting the OD value for GST from the value obtained for the fusion protein to obtain specific OD values. In the IgG subclass ELISA, a GST control was measured for each subclass tested. Positive sera were defined as those giving a specific OD above the normal range (mean ϩ 2 SD) for control European sera. Associations between antibody response and age were tested using the chi-square test for trend analysis and the Kruskal-Wallis test. The correlations between antibody response and outcome of infection were determined using the Mann-Whitney test and chi-square analysis. Since multiple comparisons were made on each data set, the critical value for P varied from 0.002 to 0.13 (0.05/number of comparisons made); see tables for details.
RESULTS
Changes in anti-MSP2 antibodies with age. Age-dependent recognition of MSP2. Anti-MSP2 IgG was measured in 178 individuals 1-75 years of age. There was an overall antibody prevalence between 47% and 88% depending on the recombinant antigen being used. The median OD increased markedly for all the antigens tested, reaching a peak after 16 years of age. The Kruskal-Wallis test indicates that this age-dependency was statistically significant (P Յ 0.008) ( Table 1) . However, the large standard deviations indicate that there was a wide range of OD values in each group, including a proportion of nonresponders.
The number of responders, i.e., antibody prevalence, was also age-dependent, with a gradual increase in prevalence through childhood, reaching a peak in adolescence ( Figure  1 ). Depending on the antigen, between 71% and 100% of this population are eventually seropositive. The chi-square test for trend indicated that the antibody prevalence for each antigen is strongly age-related. Antibodies to antigen A2 seem to be acquired more slowly than for the other antigens and the maximal antibody prevalence was lower. This could be related to the level of exposure to the T9/96 sequence of MSP2 since A2 represents a highly polymorphic repetitive region. In contrast, polymorphism in serogroup B is almost entirely due to differences in the number of repeats, rather than the sequence of the repeats, which may explain why the antibody prevalence for B2 was higher.
Analysis of OD values for positive sera (defined as one giving a specific OD above the normal range [mean ϩ 2 SD] for control European sera) alone shows that there was no significant difference in the median of the positive OD values with age (Table 2) . Thus, the age-related increase in MSP2 antibodies is due to an increase in the prevalence of antibodies with age rather than an increase in the median positive OD with age.
Age-related changes in the IgG subclass of anti-MSP2 antibodies. Sera that were known to contain MSP2-specific IgG were tested to determine the IgG subclass of the MSP2-specific antibody using a subclass specific ELISA. There was a predominance of antibodies that belong to cytophilic and complement-fixing subclasses, IgG1 and IgG3, in all age groups. The prevalence of IgG2-and IgG4-positive sera was low for all MSP2 proteins and in all age groups. In adults (21 years of age and older), the subclass distribution of MSP2-specific antibodies was essentially similar to that reported for adult sera from Brefet, The Gambia, 12 with a predominance of IgG3.
The prevalence of specific IgG3 antibodies tended to increase with age, whereas the prevalence of specific IgG1 antibodies tended to decrease (Table 3) . Although the number of MSP2-seropositive individuals in each age group was quite small, there was a clear age-related increase in IgG3 to four of the six antigens (A2, A3, B1, and B3) and an agerelated decrease in IgG1 for two antigens (A2 and B1). Figure 2 shows the median OD of the positive sera for each IgG subclass in each age group for the six antigens tested. The median OD for IgG3 antibodies clearly increased with age, and with one exception (antibodies to B2), this was statistically significant. The median OD value for IgG3 antibodies to antigen B2 was already high in the youngest age group and this may explain why a significant increase in OD with age was not observed for this antigen. A corresponding decrease in the median OD of IgG1 antibodies was apparent for the response to antigens A2, B1, and B2. Thus, overall, IgG1 antibodies were more prevalent in children less than 10 years of age, often being coexpressed with IgG3 antibodies, whereas in adolescents and adults IgG3 antibodies to MSP2 were the predominant subclass. In addition, the mean OD increased with age in IgG3 positive sera, indicating an increase in either the amount or the affinity of the MSP2-specific IgG3 antibodies.
Relationship between IgG subclass of anti-MSP2 antibodies and susceptibility to clinical malaria. Serum samples were collected from 355 children between three and eight years of age. The samples were collected in May, before malaria transmission began, and the children were monitored for malaria infection and clinical disease during the following transmission season. The sera were tested for an- 2 analysis was used to determined the correlation between antibody prevalence and clinical status after infection with malaria. Critical value for P ϭ 0.003. tibodies to MSP2 serogroup A and B antigens (A1 and B1, representing the full-length proteins of each serogroup); those sera that were positive were then tested to determine the IgG subclass and to examine the relationship with the outcome of subsequent malaria infection. The IgG subclasses of MSP2-specific antibodies were compared between individuals who subsequently developed clinical malaria and those who experienced asymptomatic infections (Table 4) . Although no significant differences were evident between the two morbidity groups in the median OD value for each antibody subclass, the prevalence of IgG3 antibodies to antigen A1 (full-length 3D7-like MSP2) was associated with a reduced risk of clinical malaria infection and the prevalence of IgG1 antibodies to antigen B1 (full-length FCQ-27-like MSP2) was associated with an increased risk of clinical malaria. Although the large number of comparisons made raises the critical value of P to 97%, the number of children in each group was small (due to the low prevalence of anti-MSP2 antibodies in this age group) and the data therefore suggest that IgG3, but not IgG1, antibodies to MSP2 are associated with resistance to clinical malaria.
DISCUSSION
The slow development of protective immunity is one of the characteristics of the naturally acquired immune response to malaria. The factors that contribute to this slow development of natural immunity have not been fully characterized but it seems likely that exposure to multiple antigenic variants of malaria parasites and age-associated maturation of the immune system are both involved. 2, 4 The decreasing incidence of mortality and morbidity with age is accompanied by increasing levels of malaria-specific antibodies. At a population level, repeated infection leads to an increase in the prevalence of antibodies to specific antigens. Within an individual, repeated exposure leads to an increase in the number of antigens, and the number of different variants of a particular antigen that are recognized. This report also provides evidence that changes in antibody subclass, which are indicative of changes in antibody function, are also associated with acquisition of protective immunity.
Previous studies on the human antibody response to malaria have focused on the antigenic specificity of the response. However, it is important to consider the quality of this response, which involves both the affinity of the F ab receptor for the antigen and the nature of the F c region, which determines antibody function. For example, some antibody-mediated mechanisms of parasite clearance require cooperation with accessory cells and it is crucial that antibodies of the appropriate subclass are induced to allow this interaction. 5, 7 In particular, antibody-mediated cellular cytotoxicity has been described as a potentially important mechanism of anti-malarial immunity and it has been proposed that effective anti-malarial immunity requires a predominance of IgG1 and IgG3 antibodies. 6 In this study we have evaluated an age cross-section of the population from a malaria endemic area to assess the evolution of the antibody response to MSP2. The prevalence of MSP2-specific IgG was markedly age-dependent, as has been described in a Papua New Guinean population. 18, 22 Overall, antibody prevalence is low in early childhood but increases to reach a peak in adolescence. Analysis of anti-MSP2 positive sera shows, however, that there is no general increase in optical density with age indicating that in seropositive individuals, the total level (and/or affinity) of MSP2-specific IgG does not increase with increasing exposure. However, this hides a marked change in IgG subclass with age. Neither the prevalence nor the median OD of IgG1, IgG2, or IgG4 antibodies increased with age, although the prevalence of IgG1 antibodies to some proteins decreased with age. In contrast, for IgG3 both the prevalence and the median OD of positive sera increased with age. The net effect of these changes in subclass prevalence was that while IgG1 predominated in young children, in malaria immune adults anti-MSP2 antibodies were almost entirely of the IgG3 subclass.
The predominance of IgG3 in the antibody response to MSP2 is unusual; although we have seen the same pattern in a different cohort of Gambians, 12 and the finding has recently been confirmed in an unrelated population in Melanesia, 13 this pattern has not been described for other malaria antigens. For example, with the same set of sera used in this study we have found that antibodies to another merozoite surface protein, MSP1 , are predominantly IgG1 in all age groups. 23 Several studies have reported that the prevalence of IgG3 responses to various malaria antigens increases with age (and/or exposure), but for antigens other than MSP2, this does not lead to IgG3 domination of the antibody response. For example, in a population in Western Kenya, IgG1 and IgG3 responses to MSP-1 were equally common and the prevalence of both subclasses increased with age. 24 In Papua New Guinea, antibodies to Pf155/ring-infected erythrocyte surface antigen, another asexual stage antigen, were found to be of a mixture of subclasses (IgG1, IgG2, and IgG3); again the prevalence of IgG3 responses increased with age. 25 Finally, in Senegal, all subclasses of IgG antibodies to a crude extract of P. falciparum-infected erythrocytes were found to increase as a function of age (although IgG4 levels were extremely low in all age groups). 26 The only other example, of which we aware, of an antigen from an infectious organism that induces such a polarized IgG3 response is the outer membrane protein of the upper respiratory tract bacterium Branhamella cattarhalis, in which the switch to IgG3 is also age-related, with specific IgG3 being essentially absent from children less than four years of age. 27 Whether this age-related shift in subclass reflects a constitutional difference between children and adults or is the result of frequent re-exposure to antigen (leading to differential class switching) is not known, although the fact that total IgG3 levels are approaching adult levels by approximately two years of age 28 suggests that age per se is not the crucial factor. The IgG1 and IgG3 subclasses are typically produced in response to protein antigens, with IgG1 in significantly greater amounts than IgG3, 28 but as yet, little is known about the factor(s) that may preferentially induce the production of IgG3. Although it is probable that T cellderived cytokines are involved in the activation of immunoglobulin switching mechanisms, by selectively inducing transcriptional activation of different constant heavy chain genes, 29 the precise requirements for switching to IgG3 in humans have not been defined. The fact that the predominance of MSP2-specific IgG3 is seen in at least two genetically distinct human populations 12, 13 suggests that MSP2 may provide an ideal system in which to address the question of control of IgG class switching in human B cells.
The shift in MSP2-specific IgG subclass distribution with age, and the predominance of the IgG3 response in adults who tend to have a high degree of protective immunity to malaria suggests that IgG3 antibodies to MSP2 may be able to mediate protective immune effector mechanisms. In a prospective longitudinal study of the susceptibility of 3-8-yearold children to clinical malaria, two significant differences in the MSP2-specific antibody response were detected between children who experienced clinical malaria and those with asymptomatic infections: there was a higher prevalence of serogroup A (3D7-like)-specific IgG3 in children with asymptomatic malaria than in children with clinical malaria, and there was a higher prevalence of serogroup B (FCQ27-like)-specific IgG1 in children with clinical malaria than in those with asymptomatic infections. We have previously shown in the same study group that children with asymptomatic infections had mean parasite densities that were 50-100-fold lower than densities in children with clinical disease, indicating that children in the asymptomatic group had developed considerable anti-parasite immunity. 30 Taken together, these results indicate that the age-related switch in MSP2-specific antibodies from IgG1 to IgG3 may be associated with the development of effective anti-parasite immunity. This is consistent with in vitro data that show that polyclonal and monoclonal antibodies specific for MSP2 inhibit parasite invasion and growth. 14, 15 It is not possible to say for sure that the changes in IgG subclass, or the antigenic specificity of the antibody, are causally associated with the resistance to clinical disease but the data are compatible with such an explanation. Previous epidemiologic studies in Papua New Guinea have indicated that antibodies to MSP2 are associated with reduced risk of fever associated with malaria infection, and with reduced risk of malaria-related anaemia, 18, 22 but did not characterize the protective IgG subclass. Conversely, a study in Senegal indicated that an increase in anti-malarial IgG3 with age was significantly associated with a decreased risk of clinical malaria, but the specificity of the antibodies was not investigated. 26 The data presented here are consistent with both of these previous studies and lend considerable support to the hypothesis that qualitative differences in the antibody response to malaria may be important in the development of protective immunity. 8 It has been proposed that IgG3 antibodies are more efficient than IgG1 at cooperating with accessory cells; 31 if so, then the ability of MSP2 to induce switching to IgG3 production may make it a particularly valuable component of the anti-malarial immune response. One potential drawback of the dominance of IgG3 in the response to MSP2 is its apparently short half-life in comparison to other IgG subclasses, 32 and it has recently been proposed that this may lead to rapid waning of immunity to malaria in the absence of re-exposure. 33 Nevertheless, data from our laboratory indicate that levels of antibodies to MSP2 in malaria immune individuals (which are almost exclusively IgG3 12 ) are remarkably stable from year to year, 34 , even in an area with seasonal transmission and an estimated infection rate of only 1-5 infectious mosquito bites per year, 1 suggesting that only infrequent reinfection is required to maintain high titers of anti-MSP2 antibody.
